Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

ConclusionsIn this post hoc analysis of four clinical trials for eptinezumab, doses of 100  mg, 300 mg, and 1000 mg (more than 3 times the highest approved dose) were not associated with clinically relevant changes in vital signs or significant changes in concomitant cardiovascular medication usage, and had low incidences of cardiovascular TEAEs, comparable to placebo.Trial registrationNCT01772524 (Study 2), 01/21/2013;NCT02275117 (Study 5), 10/27/2014;NCT02559895 (PROMISE-1), 09/25/2017;NCT02974153 (PROMISE-2), 11/28/2016
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research